At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 30, 2026 at 14:06 ET
Axsome Therapeutics announced FDA approval of AUVELITY (dextromethorphan HBr/bupropion HCl) for agitation associated with dementia due to Alzheimer's disease, a second indication for the drug. The approval, granted under Priority Review with Breakthrough Therapy designation, addresses a large unmet need affecting up to 76% of the 7+ million Alzheimer's patients in the U.S. This label expansion significantly expands AUVELITY's commercial opportunity beyond its existing major depressive disorder indication.
- FDA approved AUVELITY for agitation associated with dementia due to Alzheimer's disease on April 30, 2026
- Approval based on Phase 3 ADVANCE-1 and ACCORD-2 studies showing statistically significant improvement in agitation symptoms and longer time to relapse
- Alzheimer's disease affects >7 million Americans; agitation reported in up to 76% of patients
- AUVELITY already approved for major depressive disorder (2022) with >300,000 patients exposed and commercial infrastructure in place
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access